236 related articles for article (PubMed ID: 21262444)
1. Resistance to anti-platelet agents.
Cattaneo M
Thromb Res; 2011 Feb; 127 Suppl 3():S61-3. PubMed ID: 21262444
[TBL] [Abstract][Full Text] [Related]
2. Aspirin and clopidogrel resistance: consideration and management.
Gurbel PA; Tantry US
J Interv Cardiol; 2006 Oct; 19(5):439-48. PubMed ID: 17020569
[TBL] [Abstract][Full Text] [Related]
3. Prasugrel resistance: fact or fiction.
Alexopoulos D
Platelets; 2012; 23(2):83-90. PubMed ID: 21787175
[TBL] [Abstract][Full Text] [Related]
4. Advances in the monitoring of anti-P2Y12 therapy.
Harrison P
Platelets; 2012; 23(7):510-25. PubMed ID: 22916724
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats.
Grzesk G; Kozinski M; Navarese EP; Krzyzanowski M; Grzesk E; Kubica A; Siller-Matula JM; Castriota F; Kubica J
Thromb Res; 2012 Jul; 130(1):65-9. PubMed ID: 22265722
[TBL] [Abstract][Full Text] [Related]
6. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
[TBL] [Abstract][Full Text] [Related]
7. [Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Gratsianskiĭ NA
Kardiologiia; 2010; 50(6):4-21. PubMed ID: 20659022
[TBL] [Abstract][Full Text] [Related]
8. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S
Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors.
Storey RF
Thromb Haemost; 2011 May; 105 Suppl 1():S75-81. PubMed ID: 21479343
[TBL] [Abstract][Full Text] [Related]
10. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.
Tomasello SD; Tello-Montoliu A; Angiolillo DJ
Expert Opin Investig Drugs; 2011 Jan; 20(1):119-33. PubMed ID: 21143003
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive comparative review of adenosine diphosphate receptor antagonists.
Oh EY; Abraham T; Saad N; Rapp JH; Vastey FL; Balmir E
Expert Opin Pharmacother; 2012 Feb; 13(2):175-91. PubMed ID: 22216937
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Mousa SA; Jeske WP; Fareed J
Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
[TBL] [Abstract][Full Text] [Related]
13. Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.
Höchtl T; Tentzeris I; Schrör K; Huber K
Fundam Clin Pharmacol; 2012 Feb; 26(1):2-10. PubMed ID: 21831128
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.
Kirkby NS; Leadbeater PD; Chan MV; Nylander S; Mitchell JA; Warner TD
J Thromb Haemost; 2011 Oct; 9(10):2103-5. PubMed ID: 21812912
[No Abstract] [Full Text] [Related]
15. Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Wijeyeratne YD; Joshi R; Heptinstall S
Expert Rev Clin Pharmacol; 2012 May; 5(3):257-69. PubMed ID: 22697589
[TBL] [Abstract][Full Text] [Related]
16. Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate.
Cattaneo M
Thromb Haemost; 2011 May; 105 Suppl 1():S67-74. PubMed ID: 21479342
[TBL] [Abstract][Full Text] [Related]
17. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
[TBL] [Abstract][Full Text] [Related]
18. Smoking status and the effects of antiplatelet drugs.
Hirschl MM
BMJ; 2013 Oct; 347():f5909. PubMed ID: 24473451
[No Abstract] [Full Text] [Related]
19. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
Varenhorst C; James S; Erlinge D; Braun OO; Brandt JT; Winters KJ; Jakubowski JA; Olofsson S; Wallentin L; Siegbahn A
Am Heart J; 2009 Mar; 157(3):562.e1-9. PubMed ID: 19249429
[TBL] [Abstract][Full Text] [Related]
20. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance.
Siller-Matula J; Schrör K; Wojta J; Huber K
Thromb Haemost; 2007 Mar; 97(3):385-93. PubMed ID: 17334505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
